FDA Warning Letters: The Industry-Wide Picture
On 2026-08-30 we ran the first systematic FDA warning-letter check ever done across all 20TRT clinics we rank, plus their known operating entities — the same enforcement waves that have hit telehealth clinics marketing compounded GLP-1 medications (semaglutide, tirzepatide) since September 2025 also reach some TRT-adjacent clinics that sell weight-loss medication through the same account. Here's exactly what we found, and — just as important — where we couldn't get a confident answer.
Same query, two verticals
We run the identical FDA warning-letter methodology on our sister site, myglp1guides.com (GLP-1 weight-loss clinics). As of 2026-08-30: TRT Picks has 3 of 20 providers (15%) holding at least one open letter; myglp1guides.com has 6 of 34 providers (18%) holding at least one open letter. (A provider can hold more than one letter — Hims & Hers received two — so this counts affected providers, not raw letter count.) Same enforcement wave, same underlying FDA theory (misbranded compounded-drug marketing), different exposure by vertical — TRT clinics are less likely to also sell compounded GLP-1s than the reverse, so fewer of them get swept into this particular wave. As far as we know, no one else has run this query across both categories to compare. Read directly from myglp1guides' own data/fda-warning-letters.json on 2026-08-30 (6 of its 34 providers hold an open letter: hims, zealthy, direct-meds, ivim-health, skinnyrx, strut-health). Not live-computed at build time — the two sites are separate deployments — so this figure is only as current as the date above; re-check the sister site directly for anything more recent.
The three waves so far
- September 2025 (industry-wide, ~80 letters) — 1 of our 20 clinics hit: Hims. The first and largest wave, industry-wide. Same 3-wave breakdown verified 2026-08-28 on myglp1guides.com (sister site, GLP-1 weight-loss vertical) — ported here 2026-08-30 since it's an external FDA fact, not specific to either provider roster. Which of OUR providers were hit in each wave is computed below from each letter's own date, not hand-maintained.
- February 2026 (industry-wide, ~30 letters) — no confirmed hit among our 20 clinics. No confirmed hit among our 20 providers in this batch as of the last check — see myglp1guides.com/fda-warning-letters for the sister site's hits in this wave (Ivim Health, SkinnyRx).
- June 2026 (industry-wide, ~25 letters) — 2 of our 20 clinics hit: Maximus, Blokes. Maximus and Blokes, both issued the same day (2026-06-08) — this wave reaches some TRT-adjacent clinics that also sell compounded GLP-1 medication through the same account.
All letters cite the same core issue: FDA states compounded drugs are not FDA-approved, so marketing that implies otherwise (“same active ingredient as [brand]”, labeling that implies the seller is the compounder, etc.) makes the product misbranded under FDCA sections 502(a) and 502(bb). Every letter below is FDA's opening enforcement communication — an allegation, not a court finding or admission of wrongdoing.
This DOES affect scores here
Unlike a purely disclosure-only policy, an openFDA warning letter caps a provider's Transparency & Trust score at 4.0 — one cap per provider regardless of letter count, applied identically to every clinic including affiliate partners, and lifting automatically the moment FDA posts a closeout. See the rule on /editorial-policy. Every letter below is FDA's opening enforcement communication — an allegation, not a court finding or admission of wrongdoing.
Confirmed: 4 letters across 3 of 20 clinics we rank (0 closed out)
Hims & Hers' parent company received two letters — one per brand (Hims and Hers) — so the letter count can be higher than the affected-clinic count.
- Maximus Health, Inc. dba Maximus — MARCS-CMS 730095, 2026-06-08
- Joi and Blokes dba Joi + Blokes — MARCS-CMS 728283, 2026-06-08
- Hims & Hers Health, Inc. dba Hims — MARCS-CMS 716567, 2025-09-09
- Hims & Hers Health, Inc. dba Hers — MARCS-CMS 716825, 2025-09-09
“No letter found” is not “confirmed clean”
For the other 17clinics, we found no matching entry in FDA's public warning-letter database at the time we checked (2026-08-30). That is a real, meaningful result — but it is not the same claim as “FDA has cleared this clinic.” A few limits worth being upfront about:
- Letters arrive in waves and a clinic could be named in the next one — see the automated weekly check below.
- FDA addresses letters to a company's legal/operating entity, not always its consumer-facing brand name. For some of our 20 clinics we identified the actual operating entity (from each site's own terms of service) and searched under that name too — but for the following 2, we could not confidently pin down the operating entity beyond the brand name, so treat “no letter found” for these specifically as lower-confidence than the rest:
How we keep this current
Letters arrive in waves, so a one-time check goes stale. An automated weekly check queries FDA's public warning-letter database for each of our 20clinics and their known operating entities — and separately re-checks every letter we already hold against FDA's closeout column — opening an issue for human review whenever a new possible match or closeout appears. Nothing gets added to or changed on this page automatically; a hit (or a closeout) is only reflected here once a human has read the actual letter on fda.gov and confirmed it.
Last checked: 2026-08-30. Closeout status last verified: 2026-08-30.
This page reports regulatory facts; it is not legal advice and does not allege wrongdoing beyond what FDA itself states in each letter. An open letter caps the affected clinic's transparency score — see Editorial policy → for the exact rule.